Relapses in Wilms tumour

Carl-Magnus Kullendorff1

  • 1Division of Pediatric Surgery, Department of Pediatrics, University Hospital, 221 85 Lund, Sweden. carl-magnus.kullendorff@skane.se

Insights

Relapse in Wilms tumour (WT) is linked to high stage and unfavorable histology. While chromosome aberrations were noted, only 16q deletions strongly correlated with metastasis in this pediatric cancer study.

Area of Science:

  • Pediatric Oncology
  • Cancer Genetics
  • Clinical Research

Background:

  • Wilms tumour (WT) is a common pediatric kidney cancer.
  • Understanding relapse patterns and prognostic factors is crucial for improving outcomes.
  • Previous studies suggest links between clinical factors and WT recurrence.

Purpose of the Study:

  • To analyze relapse patterns in a cohort of children treated for Wilms tumour.
  • To identify clinical and cytogenetic factors associated with WT relapse and survival.
  • To investigate the role of specific chromosomal aberrations in WT metastasis.

Main Methods:

  • Retrospective analysis of 54 children treated for Wilms tumour over 18 years.
  • Review of clinical data including diagnosis stage, histology, and relapse sites.
  • Karyotypic analysis to detect clonal chromosome aberrations in tumor samples.

Main Results:

  • Thirteen children (24%) experienced relapse, with a mean time to first relapse of 17 months.
  • High stage at diagnosis, unfavorable histology, and nephroblastomatosis were associated with relapse.
  • Tumors with deletions of chromosome arm 16q consistently metastasized; no other significant karyotypic correlations with outcome were found.

Conclusions:

  • High stage and unfavorable histology are key indicators for relapse risk in pediatric Wilms tumour.
  • Specific chromosomal aberrations, particularly 16q deletions, may predict metastatic potential in WT.
  • Further research into the genetic underpinnings of WT relapse and metastasis is warranted.

Related Concept Videos

Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...